/

RLAY

Relay Therapeutics, Inc.Pre-market

17.98+0.10 +0.56%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delayPre-market 18.20 +1.22%

Open

17.77

Prev close

17.88

Day range

17.5318.32

52-week range

5.8521.27

Volume

2.09M0.75×

Mkt cap

3.94B

P/E ttm

—

Fwd P/E

-11.02

EPS ttm

-1.56

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−15.47%

Price Chart

Yahoo Finance · delayed

RLAYOct 12, 2026O 17.77H 18.33L 17.53C 17.98+0.10 (+0.56%)Vol 2.09M

SMA 5019.04
SMA 20014.31

1Y change +176.62% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RLAY Relay Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.27%
1 month: −4.72%
3 months: −4.00%
6 months: +17.82%
Year to date: +112.53%
1 year: +176.62%

Valuation & ownership

Market cap: 3.94B
Enterprise value: 3.06B
P/E (ttm): —
Forward P/E: -11.02
PEG ratio: —
Price / book: 4.41
Price / sales (ttm): 380.69
EV / EBITDA: -9.93
EPS (ttm): -1.56
EPS (forward): -1.63
Beta (5y monthly): 1.73
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 219.14M
Float: 145.55M
Short % of float: 24.84%
Short ratio (days): 13.32
Held by insiders: 1.58%
Held by institutions: 110.87%
Avg volume (3m): 2.77M
50-day average: 19.04
200-day average: 14.31
52-week change: +176.62%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 45.7
vs 50-day SMA: −5.57%
vs 200-day SMA: +25.69%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.46%
Realised vol (20d, ann.): 50.7%
From 52-week high: −15.47%
From 52-week low: +207.35%

ANR

Analyst Consensus

12 analysts

Consensus

Strong buy

1.23 on a 1 (strong buy) – 5 (sell) scale

Mean target

27.58

+53.41% implied

Low 20.00Median 27.50High 32.00

Recommendation trend

Now13 / 0 / 0
1m ago13 / 0 / 0

DES

About Relay Therapeutics, Inc.

Yahoo Finance profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 202
Headquarters: Cambridge, MA, United States
Website: relaytx.com
Officers: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

SEAS

Seasonality · RLAY

2020–2026 · monthly returns

Strongest month Jun +9.32%Weakest month Apr −10.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.5	33.9	-3.0	30.3	8.4	33.2	0.6	-2.4	-1.8	-0.4			+112.5%
2025	8.5	-23.7	-23.2	27.1	-9.9	15.3	1.7	2.0	45.4	36.8	10.9	6.8	+105.3%
2024	-16.0	8.3	-17.2	-21.4	-1.7	1.7	26.1	-17.4	4.3	-20.4	-16.6	-12.3	−62.6%
2023	43.6	-24.7	2.0	-31.0	-2.0	12.7	0.3	-18.9	-17.7	-21.5	19.8	39.2	−26.3%
2022	-27.9	8.9	24.1	-20.4	-31.7	2.9	13.6	20.8	-2.6	-0.7	-16.4	-19.6	−51.4%
2021	19.3	-16.8	-16.2	-8.3	1.3	13.9	-11.3	-1.3	-1.6	5.5	-11.5	4.4	−26.1%
2020								13.3	6.0	-13.3	44.3	-22.0	+17.2%

INSD

Insider Activity · RLAY

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

269K shares

Sells, 6 months

6.64M shares

Net shares

−6.37M

Net change in insider shares

−64.90%

Date	Insider	Transaction	Shares	Value
Oct 6, 2026	Patel Sanjiv NaratanbhaiChief Executive Officer	Sale at price 18.10 per share.	48.2K	$872.40K
Oct 5, 2026	Catinazzo Thomas JChief Financial Officer	Sale at price 18.58 - 19.26 per share.	17.7K	$329.32K
Sep 7, 2026	Bergstrom Donald A.Officer	Sale at price 18.97 per share.	8.5K	$161.81K
Sep 7, 2026	Patel Sanjiv NaratanbhaiChief Executive Officer	Sale at price 18.94 per share.	48.2K	$912.89K
Sep 7, 2026	Catinazzo Thomas JChief Financial Officer	Sale at price 18.94 per share.	17.7K	$335.56K
Aug 25, 2026	Rahmer Peter JOfficer	Sale at price 20.03 per share.	4.5K	$90.30K
Aug 24, 2026	Svf Pauling Cayman LtdBeneficial Owner of more than 10% of a Class of Security	Sale at price 19.40 per share.	6.00M	$116.40M
Aug 16, 2026	Patel Sanjiv NaratanbhaiChief Executive Officer	Sale at price 20.33 per share.	48.2K	$979.89K
Aug 13, 2026	Catinazzo Thomas JChief Financial Officer	Sale at price 19.74 per share.	17.7K	$349.73K
Jul 27, 2026	Rahmer Peter JOfficer	Sale at price 18.61 per share.	748	$13.92K
Jul 27, 2026	Bergstrom Donald A.Officer	Sale at price 18.61 per share.	2.2K	$41.63K
Jul 27, 2026	Catinazzo Thomas JChief Financial Officer	Sale at price 18.61 per share.	1.5K	$27.15K
Jul 6, 2026	Patel Sanjiv NaratanbhaiChief Executive Officer	Sale at price 19.58 per share.	48.2K	$943.74K
Jul 5, 2026	Bergstrom Donald A.Officer	Sale at price 18.71 per share.	8.7K	$162.03K
Jul 5, 2026	Catinazzo Thomas JChief Financial Officer	Sale at price 18.69 per share.	17.7K	$331.13K
Jun 29, 2026	Rahmer Peter JOfficer	Stock Award(Grant) at price 18.71 per share.	3.1K	$57.18K
Jun 29, 2026	Rahmer Peter JOfficer	Sale at price 19.09 per share.	50K	$954.50K
Jun 29, 2026	Patel Sanjiv NaratanbhaiChief Executive Officer	Stock Award(Grant) at price 18.71 per share.	3.1K	$57.18K
Jun 21, 2026	Bergstrom Donald A.Officer	Sale at price 16.94 per share.	93.5K	$1.58M
Jun 21, 2026	Bergstrom Donald A.Officer	Conversion of Exercise of derivative security at price 4.12 per share.	93.5K	$385.04K

13F

Investors Holding RLAY

latest 13F filings of 29 followed managers

Investors holding RLAY
Investor	Value	Of portfolio	Shares	Change	Quarter
Duquesne Family Office · Stanley Druckenmiller	$6.5M	0.13%	349.00K	New	Q2 2026
Renaissance Technologies	$3.6M	0.00%	192.40K	−71%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RLAY

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RLAY

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Relay Therapeutics, Inc.

Seasonality · RLAY

Insider Activity · RLAY

Congress Trades · RLAY

Investors Holding RLAY

Investors Holding RLAY

Congress Trades · RLAY

Insider Activity · RLAY

Seasonality · RLAY

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Relay Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News